Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21471125 | 0.81 | ALDH1A1 (0.40) | LMNAPOLBAPAF1ALDH1A1HPGD | |
| SCHEMBL21471163 | 0.80 | ALDH1A1 (0.42) | LMNAPOLBAPAF1KDM4EALDH1A1 | |
| SCHEMBL2737268 | 0.78 | LMNA (0.42) | LMNAPOLBAPAF1KDM4EALDH1A1 | |
| SCHEMBL2608929 | 0.78 | LMNA (0.62) | LMNAPOLBAPAF1KDM4EALDH1A1 | |
| SCHEMBL24350762 | 0.77 | ADORA2A (0.42) | LMNAKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL22927481 | 0.76 | ALDH1A1 (0.39) | LMNAPOLBAPAF1KDM4EALDH1A1 | |
| SCHEMBL19086915 | 0.74 | LMNA (0.42) | LMNAPOLBAPAF1KDM4EALDH1A1 | |
| SCHEMBL23403062 | 0.74 | LMNA (0.46) | LMNAPOLBAPAF1KDM4EALDH1A1 | |
| SCHEMBL22681213 | 0.74 | TSHR (0.42) | POLBMAPT | |
| SCHEMBL21462698 | 0.73 | LMNA (0.64) | LMNAPOLBAPAF1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-3774775-B1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| US-20230045509-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CABOTEGRAVIR | VIIV HEALTHCARE COMPANY | 2023-02-09 | — | — | US | disclosed |
| US-11541055-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2023-01-03 | — | — | US | disclosed |
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2020053811-A9 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2022-03-03 | — | — | WO | disclosed |
| US-20210323961-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-10-21 | — | — | US | disclosed |
| US-20200360384-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-11-19 | — | — | US | disclosed |
| WO-2019198024-A1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | LMNA 393/4885POLB 2862/4885APAF1 4768/4885 |
| US-11541055-B2 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, POLR2E, POLR2H | LMNA 3667/4885POLB 26/4885APAF1 2115/4885 |
| US-20210323961-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | LMNA 3667/4885POLB 26/4885APAF1 2115/4885 |
| US-20200360384-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | LMNA 3667/4885POLB 26/4885APAF1 2115/4885 |
| US-20230045509-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CABOTEGRAVIR | CCR5, SAMHD1, THPO | LMNA 4555/4885POLB 65/4885APAF1 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.